LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Theravance Biopharma Inc

Gesloten

10.69 1.42

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.54

Max

10.79

Belangrijke statistieken

By Trading Economics

Inkomsten

1.9M

-14M

Verkoop

-3.4M

15M

EPS

-0.173

Winstmarge

-88.244

Werknemers

97

EBITDA

-5.5M

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+77.22% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

89M

529M

Vorige openingsprijs

9.27

Vorige sluitingsprijs

10.69

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Theravance Biopharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2025, 10:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

2 jun 2025, 10:00 UTC

Acquisities, Fusies, Overnames

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

Peer Vergelijking

Prijswijziging

Theravance Biopharma Inc Prognose

Koersdoel

By TipRanks

77.22% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.75 USD  77.22%

Hoogste 24 USD

Laagste 12 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Theravance Biopharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technische score

By Trading Central

9.77 / 10.39Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.